September 30, 2011
Bookmark and Share  
 
                 
  HCV
»
»
»
»

 

Hello:

This end of the month eblast is chock full of exciting news.

HCV Advocate Newsletter—October 2011:

In This Issue:

Pharmasset: 98% to 100% Cure Rates
Alan Franciscus, Editor-in-Chief


HealthWise: Reducing the Cost of Hepatitis C Treatment
Lucinda K. Porter, RN


Disability & Benefits: Medicare Enrollment Explained
Jacques Chamber, CLU

HCV Snapshots
Lucinda K. Porter, RN

Clinical Trials
Alan Franciscus, Editor-in-Chief

The QUANTUM clinical study is a phase II interferon free study that will evaluate the safety and efficacy of Pharmasset's polymerase (nucleotide) inhibitors—PSI-7977, PSI-938 and ribavirin.

 

Hepatitis C Treatments in Current Clinical Development:
Updated September 26. Click here

Just to let you know that we have added a new feature to the Drug Pipeline: Interferon Free Trials

 

New Treatment Guidelines for Genotype 1

PDF An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases

 

Updated Factsheets:
PDFSimilarities and Differences between HIV and HCV
PDFHepatitis C and Latinos
PDFSide Effect Management: Rashes

 

Understanding HCV: A Patient Pocket Guide: Updated September 2011

To Download this Guide Click here

 

HBV Journal Review:
Updated September 30. Click here

In This Issue:

  • Young, Hepatitis B Patients Who Smoke Are at Higher Risk of Liver Cancer

  • Treatment and Monitoring Recommendations for Asian-Americans Published

  • High Doses of Lamivudine Effective in Patients with HBV-Related Cirrhosis

  • New Tests Effective in Identifying Liver Inflammation

  • Entecavir Ineffective in Patients with Lamivudine and Adefovir Resistance

  • Patients with Core Antibody—But No Surface Antigen or Antibodies—May Have Hidden Infections

and more..........

 

New: Flash Tattoo Fact Sheet:

To Download this Fact Sheet Click here

 

HBV and HCV Blog: Read about the latest and greatest in the news

 


Respectfully,

Alan

 

 

Alan Franciscus
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate www.hcvadvocate.org
Editor-in-Chief, HBV Advocate www.hbvadvocate.org

 

**Questions and Comments: Questions and/or comments can be directed to alanfranciscus@hcvadvocate.org

**To receive the eblast in your email inbox simply send an e-mail to: listserv@list.hcvadvocate.org with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.

 

 
  HBV
»
»
»
»